The limited use of GnRH agonist therapy agrees with recent evidence showing that agonist and antagonist approaches can reach similar efficacy, but GnRH antagonist treatment is often preferred as it is associated with a lower incidence of OHSS (18). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.